atai Life Sciences - Phase 1 trial of kratom-derived pharmaceutical
Despite limited scientific information, the DEA announced their intention to classify kratom, Mitragynine and 7-hydroxymitragynine as Schedule I on the Controlled Substance Act in 2016. Shortly after, a major push-back consisting of 23,000 written pleas from the general public, legislators and scientific community members challenged the DEA’s decision. For the first time in history, the DEA withdrew their intention to schedule a substance. Today, though Kratom is not a controlled substance under federal law in the US, there is little information about its pharmacological profile and therapeutic potential. But that may be about to change. Pain reliever, stimulant, religious sacrament Kratom, also known as Mitragyna speciosa , is a tree native to Thailand, Malaysia and other areas of South East Asia. The leaves of this tree have been utilized for many years by laborers for their stimulant effects and their ability to invigorate workers in harsh conditions. In addition to its stimula...